Fate Therapeutics (NASDAQ:FATE) Issues Quarterly Earnings Results

Fate Therapeutics (NASDAQ:FATE – Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.12, MarketWatch Earnings reports. Fate Therapeutics had a negative return on equity of 36.63% and a negative net margin of 253.30%. The company […]

Related Keywords

Bahram Valamehr ,Vanguard Group Inc ,Fate Therapeutics Company Profile ,Morgan Stanley ,Blackrock Inc ,Securities Exchange Commission ,Redmile Group Llc ,Wells Fargo Company ,Fate Therapeutics Inc ,Pricet Rowe Associates Inc ,Fate Therapeutics ,Get Free Report ,Marketwatch Earnings ,Therapeutics Trading Down ,Director Redmile Group ,Exchange Commission ,Street Corp ,Capital World Investors ,World Investors ,Wells Fargo ,Fate Therapeutics Daily ,